A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Erlotinib (Primary) ; Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 30 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2014 to 1 Dec 2014.
- 30 Oct 2013 Planned end date changed from 1 Dec 2013 to 1 May 2014 as reported by ClinicalTrials.gov.